AN2 Therapeutics
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events boxed warnings associated with an increased risk of respiratory conditions hypersensitivity pneumonitis bronchospasm exacerbation of underlying lung disease and hemoptysis that have led to hospitalizations in some cases other common side effects dysphonia cough upper airway irritation pain fatigue diarrhea and nausea an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
13 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events an therapeutics | AN2 Therapeutics
Related slides by other companies
23andMe
Investor Presentation
January 2024
in respiratory disease beyond | 23andMe
Kymera
Investor Presentation
June 2023
adverse events related to study drug occurring in patient | Kymera
Kymera
Results
December 2022
adverse events related to study drug occurring in patient | Kymera
Equillium
Investor Presentation
August 2023
phase first in human study of single ascending dose multiple ascending dose proof of concept study in celiac disease patients | Equillium
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io